|
|
 Previous Article | Table of Contents | Next Article 
Blood, 1 September 2002, Vol. 100, No. 5, pp. 1765-1773
IMMUNOBIOLOGY
Glucocorticoids and rituximab in vitro: synergistic
direct antiproliferative and apoptotic effects
Andrea L. Rose,
Barbara E. Smith, and
David G. Maloney
From the Fred Hutchinson Cancer Research Center,
Seattle, WA.
Rituximab, a chimeric human immunoglobulin G1
(IgG1) anti-CD20 monoclonal antibody has been shown
to mediate cytotoxicity in malignant B cells via several mechanisms in
vitro. These include direct antiproliferative and apoptotic effects,
complement-dependent cytotoxicity (CDC), and
antibody-dependent cell-mediated cytotoxicity (ADCC). Glucocorticoids
(GCs) are often administered in conjunction with rituximab in
chemotherapeutic regimens or as premedication to reduce
infusion-related symptoms. The effects of GCs on CDC and ADCC, and the
direct apoptotic and antiproliferative effects of rituximab are
unknown. Therefore, we evaluated these mechanisms in 9 B-cell
non-Hodgkin lymphoma (B-NHL) cell lines using rituximab and GCs.
Rituximab and dexamethasone induced synergistic growth inhibition in 6 B-NHL cell lines. Dexamethasone and rituximab induced significant
G1 arrest in 9 of 9 cell lines. The combination of
rituximab and dexamethasone resulted in supra-additive increases in
phosphatidylserine exposure and hypodiploid DNA content in 5 and 3 B-NHL cell lines, respectively. CDC and ADCC were neither impaired nor
enhanced when dexamethasone and rituximab were administered concurrently. However, preincubation of both effector and tumor cells
with dexamethasone reduced specific lysis in ADCC assays in 4 B-NHL
cell lines. Preincubation of tumor cell lines with dexamethasone
significantly increased cell sensitivity to CDC in 3 B-NHL cell lines.
We conclude that the addition of dexamethasone to rituximab results in
supra-additive cytotoxicity with respect to its direct
antiproliferative and apoptotic effects, induces a cell-dependent
increased sensitivity to rituximab-induced CDC, and has minimal
negative impact on ADCC when used simultaneously with rituximab.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. P. Treon, L. Ioakimidis, J. D. Soumerai, C. J. Patterson, P. Sheehy, M. Nelson, M. Willen, J. Matous, J. Mattern II, J. G. Diener, et al.
Primary Therapy of Waldenstrom Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180
J. Clin. Oncol.,
August 10, 2009;
27(23):
3830 - 3835.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Stolz, G. Hess, P. S. Hahnel, F. Grabellus, S. Hoffarth, K. W. Schmid, and M. Schuler
Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis
Blood,
October 15, 2008;
112(8):
3312 - 3321.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Dimopoulos, A. Anagnostopoulos, M.-C. Kyrtsonis, K. Zervas, C. Tsatalas, G. Kokkinis, P. Repoussis, A. Symeonidis, S. Delimpasi, E. Katodritou, et al.
Primary Treatment of Waldenstrom Macroglobulinemia With Dexamethasone, Rituximab, and Cyclophosphamide
J. Clin. Oncol.,
August 1, 2007;
25(22):
3344 - 3349.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Herold, A. Haas, S. Srock, S. Neser, K. H. Al-Ali, A. Neubauer, G. Dolken, R. Naumann, W. Knauf, M. Freund, et al.
Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study
J. Clin. Oncol.,
May 20, 2007;
25(15):
1986 - 1992.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. F. DiJoseph, M. M. Dougher, L. B. Kalyandrug, D. C. Armellino, E. R. Boghaert, P. R. Hamann, J. K. Moran, and N. K. Damle
Antitumor Efficacy of a Combination of CMC-544 (Inotuzumab Ozogamicin), a CD22-Targeted Cytotoxic Immunoconjugate of Calicheamicin, and Rituximab against Non-Hodgkin's B-Cell Lymphoma
Clin. Cancer Res.,
January 1, 2006;
12(1):
242 - 249.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. G. Maloney
Immunotherapy for Non-Hodgkin's Lymphoma: Monoclonal Antibodies and Vaccines
J. Clin. Oncol.,
September 10, 2005;
23(26):
6421 - 6428.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Jubala, J. W. Wojcieszyn, V. E. O. Valli, D. M. Getzy, S. P. Fosmire, D. Coffey, D. Bellgrau, and J. F. Modiano
CD20 Expression in Normal Canine B Cells and in Canine non-Hodgkin Lymphoma
Vet. Pathol.,
July 1, 2005;
42(4):
468 - 476.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Wojciechowski, H. Li, S. Marshall, C. Dell'Agnola, and I. Espinoza-Delgado
Enhanced Expression of CD20 in Human Tumor B Cells Is Controlled through ERK-Dependent Mechanisms
J. Immunol.,
June 15, 2005;
174(12):
7859 - 7868.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Daibata, K. Bandobashi, M. Kuroda, S. Imai, I. Miyoshi, and H. Taguchi
Induction of Lytic Epstein-Barr Virus (EBV) Infection by Synergistic Action of Rituximab and Dexamethasone Renders EBV-Positive Lymphoma Cells More Susceptible to Ganciclovir Cytotoxicity In Vitro and In Vivo
J. Virol.,
May 1, 2005;
79(9):
5875 - 5879.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Horning, A. Younes, V. Jain, S. Kroll, J. Lucas, D. Podoloff, and M. Goris
Efficacy and Safety of Tositumomab and Iodine-131 Tositumomab (Bexxar) in B-Cell Lymphoma, Progressive After Rituximab
J. Clin. Oncol.,
February 1, 2005;
23(4):
712 - 719.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ghielmini
Multimodality Therapies and Optimal Schedule of Antibodies: Rituximab in Lymphoma as an Example
Hematology,
January 1, 2005;
2005(1):
321 - 328.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. F. DiJoseph, M. E. Goad, M. M. Dougher, E. R. Boghaert, A. Kunz, P. R. Hamann, and N. K. Damle
Potent and Specific Antitumor Efficacy of CMC-544, a CD22-Targeted Immunoconjugate of Calicheamicin, against Systemically Disseminated B-Cell Lymphoma
Clin. Cancer Res.,
December 15, 2004;
10(24):
8620 - 8629.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Cartron, H. Watier, J. Golay, and P. Solal-Celigny
From the bench to the bedside: ways to improve rituximab efficacy
Blood,
November 1, 2004;
104(9):
2635 - 2642.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Okada, S. Adachi, T. Imai, K.-i. Watanabe, S.-y. Toyokuni, M. Ueno, A. S. Zervos, G. Kroemer, and T. Nakahata
A novel mechanism for imatinib mesylate-induced cell death of BCR-ABL-positive human leukemic cells: caspase-independent, necrosis-like programmed cell death mediated by serine protease activity
Blood,
March 15, 2004;
103(6):
2299 - 2307.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Dupuy, M. Viguier, C. Bedane, F. Cordoliani, S. Blaise, F. Aucouturier, J.-M. Bonnetblanc, P. Morel, L. Dubertret, and H. Bachelez
Treatment of Refractory Pemphigus Vulgaris With Rituximab (Anti-CD20 Monoclonal Antibody)
Arch Dermatol,
January 1, 2004;
140(1):
91 - 96.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Jilani, S. O'Brien, T. Manshuri, D. A. Thomas, V. A. Thomazy, M. Imam, S. Naeem, S. Verstovsek, H. Kantarjian, F. Giles, et al.
Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia
Blood,
November 15, 2003;
102(10):
3514 - 3520.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. T. C. Chan, D. Hughes, R. R. French, A. L. Tutt, C. A. Walshe, J. L. Teeling, M. J. Glennie, and M. S. Cragg
CD20-induced Lymphoma Cell Death Is Independent of Both Caspases and Its Redistribution into Triton X-100 Insoluble Membrane Rafts
Cancer Res.,
September 1, 2003;
63(17):
5480 - 5489.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Di Gaetano, E. Cittera, R. Nota, A. Vecchi, V. Grieco, E. Scanziani, M. Botto, M. Introna, and J. Golay
Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo
J. Immunol.,
August 1, 2003;
171(3):
1581 - 1587.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Sansonno, V. De Re, G. Lauletta, F. A. Tucci, M. Boiocchi, and F. Dammacco
Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20
Blood,
May 15, 2003;
101(10):
3818 - 3826.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Zaja, S. De Vita, C. Mazzaro, S. Sacco, D. Damiani, G. De Marchi, A. Michelutti, M. Baccarani, R. Fanin, and G. Ferraccioli
Efficacy and safety of rituximab in type II mixed cryoglobulinemia
Blood,
May 15, 2003;
101(10):
3827 - 3834.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
